Adebrelimab plus apatinib for SCLC maintenance
Part of Cancer clinical trials.
This study tests a new maintenance therapy (adebrelimab plus apatinib) for people with extensive-stage small cell lung cancer who have already responded to initial chemotherapy and immunotherapy. The goal is to help keep the cancer from coming back longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive-stage small cell lung cancer (cancer that has spread beyond one lung).
- You must have received 4 to 6 cycles of chemotherapy with the immunotherapy drug atezolizumab, and the cancer has not grown during that treatment.
- Your last dose of that initial treatment must be no more than 6 weeks ago.
- You cannot have serious health problems like uncontrolled high blood pressure, heart issues, bleeding problems, or certain other cancers.
- You must be willing to use effective birth control during the study and for 6 months after, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of two targeted drugs can help keep extensive-stage small cell lung cancer from growing after initial treatment. The goal is to see if this maintenance approach extends the time before the cancer worsens.
This trial tests a combination of two drugs (adebrelimab and etoposide capsules) as maintenance therapy for people with extensive-stage small cell lung cancer who have not progressed after initial treatment. It may help extend the time before the cancer grows back.
This trial tests whether adding two targeted therapies (adebelimumab, an immunotherapy, and apatinib, a drug that blocks blood vessel growth) after initial chemotherapy can help keep extensive stage small cell lung cancer under control. It is for people who have not yet had systemic treatment for their cancer and are in good enough health to try this maintenance approach.
This trial tests whether adding two drugs (adebrelimab and apatinib) after standard chemoradiation can help prevent cancer from coming back in people with limited-stage small cell lung cancer. It is for patients whose cancer did not grow after chemoradiation.
This trial tests whether continuing a drug called adebrelimab (an immunotherapy) after standard treatment helps keep limited-stage small cell lung cancer from coming back. It compares adebrelimab with the usual approach of just watching and following up.
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
Hear when a new SCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.